share_log

Baird Maintains Outperform on PTC Therapeutics, Raises Price Target to $52

Benzinga ·  Nov 27, 2024 21:08  · Ratings

Baird analyst Joel Beatty maintains PTC Therapeutics (NASDAQ:PTCT) with a Outperform and raises the price target from $48 to $52.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment